Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9,065.00
Bid: 9,060.00
Ask: 9,070.00
Change: -90.00 (-0.98%)
Spread: 10.00 (0.11%)
Open: 9,165.00
High: 9,190.00
Low: 9,030.00
Prev. Close: 9,155.00
SPX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

17 Nov 2015 07:00

RNS Number : 9064F
Spirax-Sarco Engineering PLC
17 November 2015
 

 

 

News Release

 

Tuesday 17th November 2015

TRADING UPDATE

Good performance in challenging markets

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping and associated fluid path technologies, issues the following trading update in respect of the period ended 31st October 2015. The requirement for Interim Management Statements has been removed but it is our intention to provide directional guidance via a trading update at this time of the year.

 

Trading

Global industrial production continued to grow, although at very low levels in both developed and emerging economies. There are signs that our markets in Europe, Middle East and Africa (EMEA) have stabilised, with industrial production growth modestly picking up in some markets. In the Americas, industrial production growth has continued to slow in North America and remains firmly negative in Latin America. In Asia Pacific, industrial production growth has slowed further due to China, with Korea remaining in an industrial recession.

 

Organic* sales growth in the first ten months slowed modestly, as expected, from the growth achieved in the first half. In EMEA, organic growth has continued at nearly the same pace as during the first half year, with the majority of companies showing progress. As anticipated, there has been a small improvement overall in Asia Pacific in the second half, although sales remained below the prior year, moderating slightly the sales decline in the ten months to October compared with that in the first half year. Sales in China have continued broadly flat and the level of our order books in Korea and China remain a little above this time last year. In the Americas, overall organic sales growth in the ten months to October has slowed a little compared to the first half, largely due to the anticipated deterioration in Brazil. We continue to make progress in implementing our strategy in the USA, with some improvement in underlying business levels, although organic sales remain below the prior year. As anticipated at the half year stage, the exceptional rate of organic sales growth in Watson-Marlow Fluid Technology Group (WMFTG) has been much reduced in the second half due to comparison with a period of very strong growth in the second half of 2014. The integration of Asepco, acquired in April 2015, has progressed as planned and the business is performing ahead of our expectations. Overall, currency headwinds in the second half year have continued to strengthen, reducing Group sales on translation in the first ten months by over 3% versus full-year 2014 average exchange rates. The Group's acquisitions and disposals in 2015 are anticipated to add a net 0.5% to sales for the full-year.

 

Group operating profit was slightly ahead of the comparable ten-month period at constant currency, despite the impact of start-up costs in India. The impact on profit of the lower sales growth in the second half of this year has been offset by the benefit of cost reduction actions we took in the first half year, cost savings and improved efficiency. Unfavourable currency movements have negatively impacted reported Group operating profit by 4% versus full-year 2014 average exchange rates.

 

Financial position

Our business remains highly cash generative and we maintain a strong balance sheet, with a cash neutral position at 31st October 2015, having received proceeds of £7 million from the disposal of M&M International in August 2015 and paid the special dividend of £91 million in July 2015; the linked share consolidation of 27 existing shares for 28 new shares reduces the number of shares in issue for the second half by 3.6%, benefitting earnings per share. The interim dividend for 2015 of 20.8p per share was paid in November at a cash cost of £15 million. There has been no material change in the financial position of the Group during the period.

 

Outlook

Industrial production growth has continued to slow through the year, especially in emerging markets in Latin America and Asia. However, we have continued with the implementation of our strategy aimed at generating more growth from our own actions by being more effective in identifying and generating engineered solutions to meet our customers' needs for energy and CO2 reductions, water savings, increased productivity, enhanced quality, reduced costs and compliance with increasing regulatory requirements. If recent exchange rates prevail to the end of 2015, sales for the year would be reduced on translation by 4% and operating profit reduced by 5%. Whilst we continue to have limited visibility, with short order books, and markets remain lacklustre, we have good diversification across market sectors and geographic regions and will remain focused on our strategy for growth, which, together with our fundamental strengths stand the Group in good stead. We still have much to do in the remainder of this year but our expectations for the full-year are unchanged and the Board has confidence that the Group will make further progress in 2015.

 

Spirax Sarco expects to publish its preliminary 2015 results on 3rd March 2016.

 

 

Enquiries:

Nick Anderson, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

 

Note: References to profit are to adjusted profit that excludes USA meter manufacturing facility closure costs, the amortisation and impairment of acquisition-related intangible assets and acquisition and disposal costs, together with the tax effects of these items.

* References to organic changes are excluding acquisitions and disposals, and are expressed at constant currency.

 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in each of its two businesses, Spirax Sarco for steam specialties and Watson-Marlow Fluid Technology Group for niche peristaltic pumps and associated fluid path technologies. The steam specialties business provides a broad range of fluid control products, engineered packages, site services and systems expertise for a diverse range of industrial and institutional customers. The company helps its customers to improve production efficiency, reduce energy costs, water usage and emissions, improve product quality and enhance the safety of their operations. Watson-Marlow Fluid Technology Group offers the ideal solution for a wide variety of demanding fluid path applications with highly accurate, controllable and virtually maintenance free pumps and associated technologies. The Group is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,800 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX)

Further information can be found at www.spiraxsarcoengineering.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPKADDOBDDPDD
Date   Source Headline
10th Apr 20244:44 pmRNSDirector/PDMR Shareholding
26th Mar 20249:33 amRNSDirector/PDMR Shareholding
20th Mar 202410:00 amRNSDirector/PDMR Shareholding
18th Mar 20242:34 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNS2023 Full Year Results
22nd Feb 20247:00 amRNSSpirax-Sarco Engineering rebrands as Spirax Group
1st Feb 20243:38 pmRNSChange of Director Details
30th Jan 202411:15 amRNSFuture Board Change
17th Jan 20247:00 amRNSLeadership Succession
18th Dec 20237:00 amRNSChief Financial Officer Appointment
21st Nov 20239:15 amRNSDirector/PDMR Shareholding
20th Nov 20237:00 amRNSDirector/PDMR Shareholding
20th Nov 20237:00 amRNSShare Purchases
16th Nov 20237:00 amRNSTrading Update
11th Oct 20238:40 amRNSDirector/PDMR Shareholding
25th Aug 20239:30 amRNSHolding(s) in Company
25th Aug 20238:30 amRNSHolding(s) in Company
10th Aug 20237:00 amRNS2023 Half Year Results
8th Aug 20237:00 amRNSGroup Chief Executive Succession
2nd Aug 20238:00 amRNSBoard Appointment
1st Aug 20239:09 amRNSDirector/PDMR Shareholding
27th Jul 20239:30 amRNSChange in Director Details
26th Jun 202310:00 amRNSNotice of Investment Seminar
22nd Jun 20232:03 pmRNSHolding(s) in Company
22nd Jun 20237:00 amRNSKyoto Investment and Partnership Agreement
14th Jun 202310:42 amRNSHolding(s) in Company
9th Jun 20235:45 pmRNSHolding(s) in Company
24th May 20232:46 pmRNSHolding(s) in Company
10th May 20233:23 pmRNSResult of AGM
10th May 20237:00 amRNSAGM Trading Update
16th Mar 20234:22 pmRNSDirector/PDMR Shareholding
16th Mar 20239:00 amRNSDirector/PDMR Shareholding
15th Mar 20234:12 pmRNSDirector/PDMR Shareholding
15th Mar 20239:53 amRNSDirector/PDMR Shareholding
15th Mar 20239:48 amRNSHolding(s) in Company
13th Mar 20231:31 pmRNSDirector/PDMR Shareholding
13th Mar 202312:22 pmRNSDirector/PDMR Shareholding
9th Mar 20237:00 amRNS2022 Full Year Results
8th Mar 20233:09 pmRNSChange of Director Details
21st Feb 202310:32 amRNSHolding(s) in Company
31st Jan 20239:30 amRNSBoard Changes
30th Jan 20236:04 pmRNSHolding(s) in Company
23rd Dec 202210:31 amRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSCompletion of the Acquisition of Durex Industries
17th Nov 20227:00 amRNSTrading Statement
27th Oct 20224:24 pmRNSDirector/PDMR Shareholding
4th Oct 20227:00 amRNSDirector/PDMR Shareholding
30th Sep 20227:00 amRNSCompletion of the acquisition of Vulcanic
28th Sep 20227:00 amRNSAcquisition of US Thermal Energy Specialist
6th Sep 202212:41 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.